DoW Breast Cancer, Clinical Research Extension Award
Dept. of the Army -- USAMRAA
Funding Amount
$15,400,000 total
Deadline
July 8, 2026
37 days left
Grant Type
federal
Overview
DoW Breast Cancer, Clinical Research Extension Award
Summary: The fiscal year 2026 (FY26) Breast Cancer Research Program (BCRP) Clinical Research Extension Award supports research that extends the data collection, follow-up, and analysis of breast cancer clinical studies. The intent of this award mechanism is to increase the clinically relevant impact of breast cancer patient participation in clinical studies by addressing the knowledge lost due to early trial termination, limited patient follow-up, or suboptimal sample and/or data collection and analysis. All applications must address at least one of the FY26 BCRP overarching challenges or provide adequate justification for exception . Distinctive Features: · The research team must include two or more breast cancer consumer advocates. · This funding mechanism allows for a single Principal Investigator (PI), or two partnering PIs referred to as the Initiating PI and the Partnering PI. For the Partnering PI Option (PPIO), only the Initiating PI will submit a pre-application, but both PIs will need to submit at the full application stage. Be advised, failure to submit all associated (Initiating and Partnering PI) applications by the deadline may result in administrative withdrawal.
Details
- Agency: Dept. of the Army -- USAMRAA
- Department: Department of Defense
- Opportunity #: HT942526BCRPCREA
- Total Funding: $15,400,000
- Expected Awards: 2
- Instrument: grant
Eligibility
Eligible Applicant Types
Focus Areas & Funding Uses
Fields of Work
Categories
Browse similar grants by category
Related Grants
Similar grants from this funder and related organizations
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $350,000
Deadline
September 7, 2026
Research Projects to Enhance Applicability of Mammalian Models for Translational Research (R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $499,000
Deadline
September 7, 2026
Secondary Analysis and Integration of Existing Data to Elucidate Cancer Risk and Related Outcomes (R21 Clinical Trials Not Allowed)
National Institutes of Health
Amount
Up to $200,000
Deadline
September 7, 2026
Specialized Programs of Research Excellence (SPOREs) in Human Cancers for Years 2024, 2025, and 2026 (P50 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
September 25, 2026
Innovative Research in Cancer Nanotechnology (IRCN; R01 Clinical Trial Not Allowed)
National Institutes of Health
Amount
Up to $475,000
Deadline
Closed
Understanding Expectancies in Cancer Symptom Management (R01 Clinical Trial Required)
National Institutes of Health
Amount
Varies
Deadline
Closed
Ready to apply for DoW Breast Cancer, Clinical Research Extension Award?
Grantable helps you assess fit, draft narratives, and track deadlines — so you can submit stronger applications, faster.
You found DoW Breast Cancer, Clinical Research Extension Award. Now let's win it.